Eliglustat and Renal disease
Result of checking the interaction of drug Eliglustat and disease Renal disease for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of drugs eliglustat should be avoided in patients with end-stage renal disease (estimated creatinine clearance (eCrCl) less than 15 mL/min not on dialysis or requiring dialysis). No dosage adjustment is recommended in patients with mild, moderate, or severe renal impairment (eCrCl at least 15 mL/min). In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat should be avoided in those patients with any degree of renal impairment.